PRTC vs. ONT, BVXP, OXB, HVO, AVCT, GNS, UPR, AMS, CRW, and MXCT
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Oxford Nanopore Technologies (ONT), Bioventix (BVXP), Oxford Biomedica (OXB), hVIVO (HVO), Avacta Group (AVCT), Genus (GNS), Uniphar (UPR), Advanced Medical Solutions Group (AMS), Craneware (CRW), and MaxCyte (MXCT). These companies are all part of the "medical" sector.
PureTech Health (LON:PRTC) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Oxford Nanopore Technologies has a consensus price target of GBX 303.75, indicating a potential upside of 201.40%. Given Oxford Nanopore Technologies' higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than PureTech Health.
In the previous week, Oxford Nanopore Technologies had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 1 mentions for PureTech Health. Oxford Nanopore Technologies' average media sentiment score of 0.94 beat PureTech Health's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.
80.3% of PureTech Health shares are owned by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 14.8% of PureTech Health shares are owned by company insiders. Comparatively, 30.1% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PureTech Health has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -91.06%. PureTech Health's return on equity of -7.22% beat Oxford Nanopore Technologies' return on equity.
PureTech Health received 502 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 86.58% of users gave PureTech Health an outperform vote.
PureTech Health has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
PureTech Health has higher earnings, but lower revenue than Oxford Nanopore Technologies. PureTech Health is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Oxford Nanopore Technologies beats PureTech Health on 9 of the 17 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
